Car T-Cell Therapy and Bispecific Antibodies: Frontiers in Cancer Immunology from thescientistllc on Vimeo.
Cancers are the most heterogenous group of diseases affecting humans. Multiple compensating pathways work to promote disease progression. Various immunotherapies have shown anticancer promise, but the their targeted nature limits the scope of their action and applicability. CAR T-cell therapy and bispecific antibodies are two approaches that have addressed the targeting of more than one epitope, the re-directing of T lymphocytes to kill tumor cells, and the improvement of efficacy in solid tumor types. For a closer look at the design, development, and success of CAR T-cell therapy and bispecific antibodies, The Scientist is bringing together a panel of experts to discuss their research and share insights into the potential these therapeutics hold in the fight against various tumor types. Join us to get your questions answered by our esteemed panel.
Topics to be covered:...
- Where cancer immunotherapies are living up to their promise, and where they’re falling short
- The art and science of developing novel immunotherapies
Meet the Speakers:
Bruce Levine, PhD
Netter Professor in Cancer Gene Therapy
Founding Director, Clinical Cell and Vaccine Production Facility
Center for Cellular Immunotherapies Deputy Director
– Technology Innovation and Assessment
Department of Pathology and Laboratory Medicine
Perelman School of Medicine, Abramson Cancer Center
University of Pennsylvania
John H. Sampson, MD, PhD, MBA, MHSc
Robert H. and Gloria Wilkins Professor of Neurosurgery
Chair, Department of Neurosurgery
Duke University Medical Center
Interested in reading more?
The Scientist ARCHIVES
Become a Member of
